CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLYM CLIMB BIO INC

Market Closed 03-20 16:00:00 EDT

6.11

-0.87

-12.46%

盘后6.00

-0.11-1.80%

17:48 EDT

High7.11	Low6.00	Vol564.91K
Open6.92	D1 Closing6.98	Amplitude15.83%
Mkt Cap291.86M	Tradable Cap186.97M	Total Shares47.77M
T/O3.62M	T/O Rate1.85%	Tradable Shares30.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLYM","market":"US","secType":"STK","nameCN":"CLIMB BIO INC","latestPrice":6.11,"timestamp":1774036800000,"preClose":6.98,"halted":0,"volume":564910,"hourTrading":{"tag":"盘后","latestPrice":6,"preClose":6.11,"latestTime":"17:48 EDT","volume":14875,"amount":90526.4075,"timestamp":1774043293290,"change":-0.11,"changeRate":-0.018003,"amplitude":0.022913},"delay":0,"changeRate":-0.12464183381088827,"floatShares":30599941,"shares":47768000,"eps":-0.897422,"marketStatus":"Market Closed","change":-0.87,"latestTime":"03-20 16:00:00 EDT","open":6.92,"high":7.105,"low":6,"amount":3619819.0168,"amplitude":0.158309,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.897422,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":6.98,"preHourTrading":{"tag":"盘前","latestPrice":6.93,"preClose":6.98,"latestTime":"09:29 EDT","volume":4,"amount":27.72,"timestamp":1774013342043,"change":-0.05,"changeRate":-0.007163,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":6,"preClose":6.11,"latestTime":"17:48 EDT","volume":14875,"amount":90526.4075,"timestamp":1774043293290,"change":-0.11,"changeRate":-0.018003,"amplitude":0.022913},"volumeRatio":1.2527710530196958,"impliedVol":5.8485,"impliedVolPercentile":0.9756},"requestUrl":"/m/hq/s/CLYM","defaultTab":"news","newsList":[{"id":"2620232592","title":"Climb Bio Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620232592?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:34","pubTimestamp":1773830040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 06:34 ET (10:34 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2620238304","title":"U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620238304?lang=en_us&edition=fundamental","pubTime":"2026-03-18 15:36","pubTimestamp":1773819417,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Factset, Lensar, StarbucksMarch 18 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, including Fa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4060HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMG7P926.USD","DLR","GLXY","APD","GEMG","GEMI","GLXU","LU2360107671.USD","COHR","ANDG","BTGO","FDS","CTMX","COHX","ALDX","EQIX","XYZG","ASO","FICO","DTE","CCL","XYZY","EVMN","CLYM","GLGG","ETR","CADL","CLH","CALM","BTSG","ARCT","DOW","STZ","BKKT","DOCU","CF","DUOL","DC","CRC","GHM","ECL","HQY","LU1923621640.USD","LU1992135472.HKD","CE","ANRO","BL","XYZ","APGE","AJG"],"gpt_icon":0},{"id":"2618941694","title":"Climb Bio Inc : Raymond James Initiates Coverage With Strong Buy Rating; Target Price $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2618941694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618941694?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:29","pubTimestamp":1773228591,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ0M1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2618916466","title":"U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2618916466","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618916466?lang=en_us&edition=fundamental","pubTime":"2026-03-11 15:10","pubTimestamp":1773213002,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, OracleMarch 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wednesday, includin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"73f0b19cff544fe0a24216c0d940c1eb","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL4N3ZZ0GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBG","H","HWM","RNA","NKE","ORCX","HIMZ","CLYM","BMRN","ORCS","EXPE","ABM","CHH","DBI","BKNG","EPRT","AVR","HIMS","ABT","HAS","PGNY","FICO","HIYY","CDW","APYX","GEHC","BSX","AVXX","HIMY","ADC","T","BLND","HAE","HMYY","SJM","DXCM","ELV","ORCL","ORCU","HOG","REGN","CNC","UEC","BKNU","MET","ALMS","AVAV","CASY","CNCG","HLT"],"gpt_icon":1},{"id":"2618937870","title":"Climb Bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937870","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937870?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:40","pubTimestamp":1773142800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 07:40 ET (11:40 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLYM","BK4139","BK4539"],"gpt_icon":0},{"id":"2618893914","title":"Climb Bio price target raised to $15 from $11 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618893914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618893914?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:15","pubTimestamp":1773137747,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $15 from $11 and keeps a Buy rating on the shares ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-15-from-11-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-15-from-11-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2618826939","title":"Climb Bio, Inc. : H.c. Wainwright Raises Target Price to $15 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2618826939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618826939?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:11","pubTimestamp":1773137508,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nAZN4SKHSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2618984183","title":"U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx","url":"https://stock-news.laohu8.com/highlight/detail?id=2618984183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618984183?lang=en_us&edition=fundamental","pubTime":"2026-03-10 15:23","pubTimestamp":1773127423,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Caseys General Stores, FedEx March 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL4N3ZY0IY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CASY","HIMZ","ARCB","ADBE","BIOA","FCEL","IE00B7SZL793.SGD","LU1941712264.USD","ADBG","TGT","CRWL","BBIO","DNTH","HIMS","BYRN","CCC","HCA","FDX","LRCU","CLRB","GTLB","FIVE","PSTG","HPE","NXT","KFY","ALEC","CDE","CRWD","HMYY","FIGR","GILD","CLYM","MAZE","AMGN","CROX","FSS","HIYY","ADEA","LRCX","BETA","HIMY","DOW","AAOI","GO","IE00B19Z6F94.USD","MGNX","CELC","CHWY"],"gpt_icon":1},{"id":"2617907638","title":"Wedbush Raises Price Target on Climb Bio to $14 From $12, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2617907638","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617907638?lang=en_us&edition=fundamental","pubTime":"2026-03-06 21:28","pubTimestamp":1772803720,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $12.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2617952057","title":"Climb Bio price target raised to $12 from $9 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2617952057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617952057?lang=en_us&edition=fundamental","pubTime":"2026-03-06 02:10","pubTimestamp":1772734214,"startTime":"0","endTime":"0","summary":"Baird raised the firm’s price target on Climb Bio (CLYM) to $12 from $9 and keeps an Outperform rating on the shares. Published first on TheFly – t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-12-from-9-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/climb-bio-price-target-raised-to-12-from-9-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2617528940","title":"Climb Bio Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2617528940","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617528940?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:51","pubTimestamp":1772718660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLYM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 08:51 ET (13:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0},{"id":"2617542287","title":"Wedbush Initiates Climb Bio at Outperform With $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542287","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542287?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:49","pubTimestamp":1772714980,"startTime":"0","endTime":"0","summary":"Climb Bio (CLYM) has an average rating of buy and mean price target of $11.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2617544359","title":"Climb Bio Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $12.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544359?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:17","pubTimestamp":1772713061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT11C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","CLYM"],"gpt_icon":0},{"id":"2617046541","title":"Climb Bio Q4 EPS $(0.26) Misses $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617046541","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617046541?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:13","pubTimestamp":1772712831,"startTime":"0","endTime":"0","summary":"Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 46.07 percent. This is a 100 percent decrease over losses of $(0.13) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51062310/climb-bio-q4-eps-0-26-misses-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","CLYM"],"gpt_icon":0},{"id":"2617410435","title":"Climb Bio Inc - Qtrly EPS $-0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2617410435","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617410435?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:13","pubTimestamp":1772712800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT0FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLYM","BK4539","BK4139"],"gpt_icon":0},{"id":"2617541230","title":"Climb Bio Q4 R&D expenses rise to USD 13.7 million (+130.5%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541230","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541230?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:02","pubTimestamp":1772712152,"startTime":"0","endTime":"0","summary":"Climb Bio reported a Q4 2025 net loss of USD 17.5 million and a FY 2025 net loss of USD 59.9 million. Q4 R&D expenses were USD 13.7 million  and Q4 G&A expenses were USD 5.6 million , while FY 2025 R&D expenses were USD 46.7 million  and FY 2025 G&A expenses were USD 21.2 million . Other income, net was USD 1.8 million in Q4 2025  and USD 8.0 million in FY 2025 . Cash, cash equivalents and marketable securities totaled USD 160.7 million as of Dec. 31, 2025, which Climb Bio said is expected to fund operations into 2028. On the business side, Climb Bio said dosing is complete in a Phase 1 healthy-volunteer study of a subcutaneous formulation of budoprutug, with data expected in H1 2026. The company said enrollment is ongoing in its budoprutug trials in primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, with initial data from all three studies expected in H2 2026; it also expects first patient dosed in a China SLE study in H1 2026. For CLYM116, Climb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL8RKDGf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","BK4585","BK4139","SG9999014013.SGD","LU0314104364.USD","LU2095319765.USD","CLYM","BK4112","BK4588","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4539"],"gpt_icon":0},{"id":"2617411075","title":"Press Release: Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617411075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617411075?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026. Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026. Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026. WELLESLEY HILLS, Mass., March 05, 2026  -- Climb Bio, Inc. , a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.previously treated patients with ITP is designed to evaluate safety,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","BK4199","BK4539","BK4077","BK4109","ASH","SLE","ITP","IND","BK4139","CLYM"],"gpt_icon":0},{"id":"2617545487","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2617545487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617545487?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:00","pubTimestamp":1772708400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CPI Card Grp                                    4Q       .65   7:00 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCIC","BODI","BLND","BURL","AQN","ACCO","CTOS","BBCP","AMTX","AMBQ","AEYE","ACET","AKA","ALGS","ALT","BRLT","ABM","CANG","CCEC","CHRS","BETA","CING","APYX","CRMD","FCEL","ALNT","CTNM","CLAR","ATHM","CNQ","CRVS","BNTX","COO","COST","COOK","CASY","ADCT","AMPX","CLYM","OLPX","ARQ","CIEN","BJ","BVS","CGEM","ASMB","ANNX","BTAI"],"gpt_icon":1},{"id":"2617751632","title":"U.S. RESEARCH ROUNDUP-Broadcom, CNX Resources, Veeva Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2617751632","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617751632?lang=en_us&edition=fundamental","pubTime":"2026-03-05 15:16","pubTimestamp":1772695016,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Broadcom, CNX Resources, Veeva SystemsMarch 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Broa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL8N3ZT0FO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","CRC","BRBR","VEEV","AAPY","AVGG","CBRL","CCOI","AAPX","AZO","CLYM","CCI","CRWG","APP","CSR","CON","AMT","AFRM","RCEL","ANF","BLLN","XYZ","CCL","CHRD","AEO","AAPB","LEU","CRWV","AVGX","CRWD","BBY","CHWY","AAPL","COHR","COP","CTRA","AVGO","CCRN","AVGW","ASPN","TGT","AR","CRWU","MACW.SI","APPX","BGS","BBWI","CALC","APA","CNX"],"gpt_icon":1},{"id":"2614862188","title":"Climb Bio Director Thomas Stephen Basil Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614862188","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614862188?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:05","pubTimestamp":1772226350,"startTime":"0","endTime":"0","summary":"Thomas Stephen Basil, a director of Climb Bio, Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDLbq6q7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Climb Bio Director Thomas Stephen Basil Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","CLYM","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eliemtx.com","stockEarnings":[{"period":"1week","weight":-0.1309},{"period":"1month","weight":0.1109},{"period":"3month","weight":0.4276},{"period":"6month","weight":1.645},{"period":"1year","weight":3.7734},{"period":"ytd","weight":0.5275}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012175},{"month":2,"riseRate":0.6,"avgChangeRate":0.088588},{"month":3,"riseRate":0.2,"avgChangeRate":-0.110924},{"month":4,"riseRate":0.75,"avgChangeRate":0.286337},{"month":5,"riseRate":0.5,"avgChangeRate":0.027501},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069889},{"month":7,"riseRate":0.75,"avgChangeRate":0.07628},{"month":8,"riseRate":0.25,"avgChangeRate":0.096778},{"month":9,"riseRate":0.2,"avgChangeRate":-0.124516},{"month":10,"riseRate":0.4,"avgChangeRate":-0.049478},{"month":11,"riseRate":0,"avgChangeRate":-0.130257},{"month":12,"riseRate":0.6,"avgChangeRate":0.177771}],"exchange":"NASDAQ","name":"CLIMB BIO INC","nameEN":"CLIMB BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLIMB BIO INC,CLYM,CLIMB BIO INC股票,CLIMB BIO INC股票老虎,CLIMB BIO INC股票老虎国际,CLIMB BIO INC行情,CLIMB BIO INC股票行情,CLIMB BIO INC股价,CLIMB BIO INC股市,CLIMB BIO INC股票价格,CLIMB BIO INC股票交易,CLIMB BIO INC股票购买,CLIMB BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLIMB BIO INC(CLYM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLIMB BIO INC(CLYM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}